COMPARISON OF THREE HOMOEOPATHIC DRUGS FOR COVID 19 IMMUNE BOOSTERS AGAINST STANDARD TREATMENT

A Community based Cluster Randomized Open Level Controlled Field Trial to Evaluate the Effectiveness of Homoeopathic Prophylaxis and Standard Prophylaxis against CVOID -19

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/07/026953

Enrollment

704

Registered

2020-07-31

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: ARSENICUM ALBUM 30: 4-6 GLOBULES OD FOR THREE DAYS REPEATED AT 15 DAYS INTERVAL FOR 45 DAYS Intervention2: SARCOLACTIC ACID 30: 4-6 GLOBULES OD FOR THREE DAYS REPEATED AT 15 DAYS INTER

Eligibility

Inclusion criteria

Inclusion criteria: Adult Male or Female subjects above the age of 18 years to 68 years 2. Subjects who are from a community where at least 1 confirmed case is already identified. 3. Subjects who are ready to provide written/digital informed consent and who are willing to participate and follow the protocol requirements of the clinical study

Exclusion criteria

Exclusion criteria: 1. Pregnant and Lactating females 2. Known cases of uncontrolled Diabetes and Hypertension. 3. Subjects having any medical or surgical condition that would require immediate medical or surgical intervention at the time of screening 4. Subjects having immune compromised status like HIV, Hepatitis, Tuberculosis, Cancer etc. 5. Subjects taking Steroid treatment and or any kind of immunosuppressive therapy 6. Subjects participating in any other clinical study or having participated in any other study 1 month prior to screening in the present study. 7. Subjects having a past history of allergy to any medicine that is part of the Homoeopathic intervention. 8. Other conditions, which in the opinion of the investigators, makes the patient unsuitable for enrolment or could interfere with his participation in, and completion of the protocol 9. Patients having heart disease, kidney disease

Design outcomes

Primary

Measure	Time frame
Immune Status Questionnaire WHO -QOL -BREF QuestionnaireTimepoint: O Days -15 Days- 30 Days -45 Days	—

Secondary

Measure	Time frame
Any one getting any adverse events following the medicineTimepoint: 0 days 15 days 30 days 45 days	—

Countries

India

Contacts

Public ContactDR PRASANTA RATH

NATIONAL INSTITUTE OF HOMOEOPATHYBLOCK GE SECTOR III SALT LAKE KOLKATA

drprasantarath09@gmail.com8420924836

Outcome results